1610527-49-5

Basic information

• Product Name: (2,4-diMethylphenyl)(2-nitrophenyl)sulfane
• Synonyms: (2,4-diMethylphenyl)(2-nitrophenyl)sulfane;2,4-Dimethyl-1-[(2-nitrophenyl)thio]benzene;(2,4-Dimethyiphenyl)(2-Nitrophenyl)Sulfane
• CAS NO: 1610527-49-5
• Molecular Formula: C14H13NO2S
• Molecular Weight: 259.32352
• EINECS: -0
• Mol File: 1610527-49-5.mol

Chemical Properties

• Boiling Point: 353.9±30.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (2,4-diMethylphenyl)(2-nitrophenyl)sulfane(CAS DataBase Reference)
• NIST Chemistry Reference: (2,4-diMethylphenyl)(2-nitrophenyl)sulfane(1610527-49-5)
• EPA Substance Registry System: (2,4-diMethylphenyl)(2-nitrophenyl)sulfane(1610527-49-5)

Safety Data

• Hazardous Substances Data: 1610527-49-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2,4-diMethylphenyl)(2-nitrophenyl)sulfane is used as a reactant for studying the generic industry approach to efficient purification of potential mutagenic impurities in the synthesis of drug substances. Its application is crucial in ensuring the safety and quality of the final drug products by minimizing the presence of harmful impurities that could pose health risks to patients.
In the context of drug synthesis, (2,4-diMethylphenyl)(2-nitrophenyl)sulfane aids in the development of processes that can effectively separate and remove mutagenic impurities, which are byproducts formed during the chemical reactions involved in drug production. By employing this compound as a reactant, researchers and pharmaceutical companies can optimize their purification techniques, leading to the production of drugs with higher purity and fewer potential side effects.
Furthermore, the use of (2,4-diMethylphenyl)(2-nitrophenyl)sulfane in the pharmaceutical industry also contributes to the overall improvement of drug manufacturing processes. By focusing on the efficient purification of mutagenic impurities, this compound helps to enhance the overall quality and safety of drug substances, ultimately benefiting patients and the healthcare sector as a whole.

Upstream product

• 13616-82-5 2,4-dimethyl-thiophenol 
• 88-73-3 2-Chloronitrobenzene 
• 577-19-5 2-nitrophenyl bromide 
• 365-33-3 2-nitrobenzenediazonium tetrafluoroborate 
• 89816-81-9 2,4-dimethylphenyl ethyl xanthate 
• 95-68-1 2,4-Xylidine 
• 4875-10-9 o-nitrothiophenol 
• 583-70-0 1-bromo-2,4-dimethylbenzene 
• 4214-28-2 1-iodo-2,4-dimethylbenzene 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 508233-74-7 vortioxetine 
• 960203-28-5 Vortioxetine hydrochloride 
• 960203-27-4 Vortioxetine hydrobromide 
• 960203-41-2 (2′-bromophenyl)(2,4-dimethylphenyl)sulfane 

Relevant articles and documents

Chemoselective Hydrogenation of Nitroarenes Using an Air-Stable Base-Metal Catalyst

The reduction of nitroarenes to anilines as well as azobenzenes to hydrazobenzenes using a single base-metal catalyst is reported. The hydrogenation reactions are performed with an air-and moisture-stable manganese catalyst and proceed under relatively mild reaction conditions. The transformation tolerates a broad range of functional groups, affording aniline derivatives and hydrazobenzenes in high yields. Mechanistic studies suggest that the reaction proceeds via a bifunctional activation involving metal-ligand cooperative catalysis.

Preparation method of 1-[2-(2, 4-dimethylthiophenyl)-phenyl]piperazine

The invention relates to a preparation method of 1-[2-(2,4-dimethylthiophenyl)-phenyl]piperazine. The method comprises the steps that 2,4-dimethylthiophenol and 1-halogen-2-nitrobenzene carry out a substitution reaction to prepare 2-(2,4-dimethylthiophenyl) nitrobenzene, 2-(2,4-dimethylthiophenyl) nitrobenzene is reduced to prepare 2-(2,4-dimethylthiophenyl)aniline, and 2-(2,4-dimethylthiophenyl)aniline and bis(2-chloroethyl)amine hydrochloride carry out a cyclization reaction to prepare 1-[2-(2,4-dimethylthiophenyl)-phenyl]piperazine. According to the preparation method, 2,4-dimethylthiophenol and 1-halogen-2-nitrobenzene are used as starting materials, and a substitution reaction, a reduction reaction and a cyclization reaction are carried out to prepare the target compound. The three-step reaction is low in cost, high in yield and easy to purify and industrialize.

Metal-Free Cercosporin-Photocatalyzed C-S Coupling for the Selective Synthesis of Aryl Sulfides under Mild Conditions

Aryl sulfides are important motifs of bioactive molecules, which are generally synthesized by transition metal-based coupling reactions under harsh conditions. Herein, we developed a new method that visible light along with cercosporin, produced by liquid fermentation and functioned as a cost-effective and environmentally friendly photocatalyst, prompted the selective synthesis of aryl sulfides through C–S coupling of thiols and diazonium salts under mild conditions. Furthermore, this method can also be performed with a great conversion by the direct use of cercosporin-containing fermentation supernatant as catalytic system without organic solvent extraction.

AN IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE HYDROBROMIDE

The present invention is related to an improved process for the preparation and purification of crystalline polymorph of Vortioxetine hydrobromide of Formula-I and Vortioxetine hydrochloride of Formula-Ia. The process according to present invention is operationally simple and suitable for industrial application which will avoid hazardous chemicals and eliminate column chromatography to get ICH quality of pharmaceutically acceptable active pharmaceutical ingredient having snow white appearance.

Synthesis and biological evaluation of some bicyclic [2-(2,4-dimethylphenylthio)phenyl] aniline and its amide derivatives as potential antitubercular agents

Abstract: In the present investigation, a series of bicyclic [2-(2,4-dimethylphenylthio)phenyl] aniline analogues were synthesized and characterized by IR, NMR (1H and 13C) and mass spectra. All newly synthesized 15 compounds were inspected for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H 37Ra in both active and dormant state using an established XTT Reduction Menadione assay (XRMA). The titled compounds exhibited minimum inhibitory concentration (MIC90) ranging from 0.05 to?>30 (μ g/mL). The potent four compounds were further evaluated in THP-1 infection model where they demonstrated significant antitubercular activity. All the ex vivo active were further evaluated for cytotoxic activity against THP-1, MCK-7 and HeLa cell lines in order to check selectivity index. All compounds were further screened against four different bacteria to assess their selectivity towards MTB. These derivatives could be considered as a precursor structure for further design of antituberculosis agent. Graphical Abstract: SYNOPSIS A series of bicyclic [2-(2,4-dimethylphenylthio)phenyl] aniline analogues were synthesized. All newly synthesized 15 compounds were inspected for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H 37Ra in both active and dormant state using an established XTT Reduction Menadione assay (XRMA).[Figure not available: see fulltext.].

1-[2-(2,4-dimethylphenylsulfydryl)phenyl]piperazine hydrochloride and preparation method thereof

The invention discloses 1-[2-(2,4-dimethylphenylsulfydryl)phenyl]piperazine hydrochloride and a preparation method thereof. By means of the specific preparation method, the HPLC purity of vortioxetinehydrochloride is higher than 99.5%, and the content of

fertile for the west sandbank synthetic method

The invention discloses a synthetic method of vortioxetine. The synthetic method comprises the following steps of by adopting a compound as shown in a formula (I) as a raw material, carrying out substitution reaction on the compound and 2,4-dimethyl thiophenol (II) to generate 2-(2,4-dimethyl phenyl alkyl sulfide) nitrobenzene (III); reducing 2-(2,4-dimethyl phenyl alkyl sulfide) nitrobenzene (III) to obtain 2-(2,4-dimethyl phenyl alkyl sulfide) phenylamine (IV); cyclizing 2-(2,4-dimethyl phenyl alkyl sulfide) phenylamine (IV) and N,N-bis(2-chloroethyl)-4-methyl benzsulfamide (VI) to obtain Tos-protecting vortioxetine (V); and preparing vortioxetine (VII) from Tos-protecting vortioxetine (V) under the action of a phenol additive. The synthetic method disclosed by the invention has the advantages of easily available raw material, simple process, low cost and high purity, and is suitable for industrialized production.

PROCESS FOR PREPARATION OF VORTIOXETINE HYDROBROMIDE

The present invention provides a process for preparation of Vortioxetine hydrobromide (I). The present invention also relates to the novel intermediate and its use in preparation of vortioxetine hydrobromide (I).

NOVEL POLYMORPHIC FORMS OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortioxetine hydrobromide and a stable amorphous co-precipitate of Vortioxetine hydrobromide with pharmaceutically acceptable excipients.

Preparation method of vortioxetine hydrobromide

The invention relates to the technical field of preparation of vortioxetine hydrobromide, in particular to a preparation method of vortioxetine hydrobromide. The preparation method comprises the following steps: taking 2,4-dimethyl thiophenol as a raw material to react with o-bromonitrobenzene so as to generate a compound (IV); treating the compound (IV) via a normal pressure catalytic hydrogenation method to obtain a compound (V); treating the compound (V) via a Sandmeyer reaction to obtain a compound (VI); and reacting a compound (VII) with piperazine, and then performing a reaction with hydrobromic acid to generate a salt, thereby obtaining a target compound (I). The method for preparing vortioxetine hydrobromide is relatively short in route, relatively mild in reaction condition, simple, convenient and feasible in after treatment, and more suitable for industrial production requirements.